These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33495227)

  • 1. Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy.
    Petersson J; Giske CG; Eliasson E
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
    Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
    Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
    Roberts JA; Joynt GM; Lee A; Choi G; Bellomo R; Kanji S; Mudaliar MY; Peake SL; Stephens D; Taccone FS; Ulldemolins M; Valkonen MM; Agbeve J; Baptista JP; Bekos V; Boidin C; Brinkmann A; Buizen L; Castro P; Cole CL; Creteur J; De Waele JJ; Deans R; Eastwood GM; Escobar L; Gomersall C; Gresham R; Jamal JA; Kluge S; König C; Koulouras VP; Lassig-Smith M; Laterre PF; Lei K; Leung P; Lefrant JY; Llauradó-Serra M; Martin-Loeches I; Mat Nor MB; Ostermann M; Parker SL; Rello J; Roberts DM; Roberts MS; Richards B; Rodríguez A; Roehr AC; Roger C; Seoane L; Sinnollareddy M; Sousa E; Soy D; Spring A; Starr T; Thomas J; Turnidge J; Wallis SC; Williams T; Wittebole X; Zikou XT; Paul SK; Lipman J;
    Clin Infect Dis; 2021 Apr; 72(8):1369-1378. PubMed ID: 32150603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
    Petersson J; Giske CG; Eliasson E
    Acta Anaesthesiol Scand; 2016 Nov; 60(10):1425-1436. PubMed ID: 27655029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
    Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
    Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
    Jamal JA; Udy AA; Lipman J; Roberts JA
    Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
    Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
    Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperacillin Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Foissac F; Bouazza N; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0113522. PubMed ID: 36342152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
    Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
    Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study.
    Liebchen U; Paal M; Bucher V; Vogeser M; Irlbeck M; Schroeder I; Zoller M; Scharf C
    J Crit Care; 2022 Feb; 67():26-32. PubMed ID: 34628123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-lactam antibiotic concentrations during continuous renal replacement therapy.
    Beumier M; Casu GS; Hites M; Seyler L; Cotton F; Vincent JL; Jacobs F; Taccone FS
    Crit Care; 2014 May; 18(3):R105. PubMed ID: 24886826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
    Schatz LM; Brinkmann A; Röhr A; Frey O; Greppmair S; Weinelt F; Zoller M; Scharf C; Hempel G; Liebchen U
    Antimicrob Agents Chemother; 2023 May; 67(5):e0010423. PubMed ID: 37125925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical Practice.
    Scharf C; Paal M; Schroeder I; Vogeser M; Draenert R; Irlbeck M; Zoller M; Liebchen U
    Antibiotics (Basel); 2020 Mar; 9(3):. PubMed ID: 32245195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing.
    Gatti M; Giannella M; Raschi E; Viale P; De Ponti F
    J Antimicrob Chemother; 2021 Jan; 76(1):199-205. PubMed ID: 33057628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.